Abstract
A number of studies have reported an association between increased levels of antibodies against oxidized low-density lipoprotein (oxLDL) and cardiovascular disease, but the anti-oxLDL antibody has not been confirmed to serve as an effective biomarker for prediction of acute myocardial infarction (AMI). Apolipoprotein B100 (ApoB100)-derived peptide fragments generated by proteolytic degradation and aldehyde modification are the major antigens in oxLDL, and so the present work was undertaken to detect circulating IgG for Apo-B100-derived peptide antigens. An in-house enzyme-linked immunosorbent assay (ELISA) was developed with eight ApoB100-derived peptide antigens (Ag1–Ag8) to detect circulating anti-ApoB100 IgG levels in 267 patients with AMI and 201 control subjects. Binary logistic regression analysis revealed that circulating IgG for Ag1 was significantly higher in the patient group than the control group (P<0.001) after adjustment for age, gender, smoking, hypertension, diabetes and circulating levels of cholesterol, HDL, LDL, ApoA and ApoB100. None of the other seven antigens detected an increase in IgG levels in AMI patients compared with control subjects. Spearman correlation analysis showed no correlation between IgG antibody for Ag1 and clinical characteristics. In conclusion, the linear peptide antigens derived from ApoB100 may be suitable for the development of an ELISA antibody test for prediction of AMI, although further confirmation is still needed in large-scale clinical studies.
Highlights
Acute myocardial infarction (AMI) is defined as myocardial cell death due to prolonged ischemia [14], characterized mainly by rupture or erosion of coronary atherosclerotic plaque and subsequent complete or incomplete occlusive thrombosis
There are numerous studies demonstrating the association between circulating anti-oxidized low-density lipoprotein (oxLDL) antibodies and cardiovascular disease, but the results reported to date have been inconsistent
The inter-assay deviation that represents the reproducibility of the in-house enzyme-linked immunosorbent assay (ELISA) test was estimated using specific binding index (SBI) tested with pooled serum samples, namely quality control (QC) samples that were randomly collected from 100 healthy subjects and tested on every 96-well plate
Summary
Acute myocardial infarction (AMI) is defined as myocardial cell death due to prolonged ischemia [14], characterized mainly by rupture or erosion of coronary atherosclerotic plaque and subsequent complete or incomplete occlusive thrombosis. The oxidative modification of LDL leads to the formation of immunogenic epitopes that can induce the secretion of specific antibodies against oxLDL [29,1]. There are numerous studies demonstrating the association between circulating anti-oxLDL antibodies and cardiovascular disease, but the results reported to date have been inconsistent. Some studies have determined a positive correlation between the levels of circulating anti-oxLDL antibodies and atherosclerotic diseases, whereas others have shown an opposite result [3,12,11,33,16,2,34]. The present work was undertaken to develop an in-house enzyme-linked immunosorbent assay (ELISA) with ApoB100-derived linear peptide antigens to detect circulating IgG antibodies against these linear peptides in AMI
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
